CU20000140A7 - Combinaciones de estatina-carboxialquileter - Google Patents

Combinaciones de estatina-carboxialquileter

Info

Publication number
CU20000140A7
CU20000140A7 CU20000140A CU20000140A CU20000140A7 CU 20000140 A7 CU20000140 A7 CU 20000140A7 CU 20000140 A CU20000140 A CU 20000140A CU 20000140 A CU20000140 A CU 20000140A CU 20000140 A7 CU20000140 A7 CU 20000140A7
Authority
CU
Cuba
Prior art keywords
statin
carboxialquileter
combinations
composition
carboxyalkylether
Prior art date
Application number
CU20000140A
Other languages
English (en)
Spanish (es)
Inventor
Roger Schofield Newton
Charles Larry Bisgaier
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of CU20000140A7 publication Critical patent/CU20000140A7/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CU20000140A 1997-12-12 2000-06-09 Combinaciones de estatina-carboxialquileter CU20000140A7 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6937597P 1997-12-12 1997-12-12

Publications (1)

Publication Number Publication Date
CU20000140A7 true CU20000140A7 (es) 2005-10-19

Family

ID=22088573

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20000140A CU20000140A7 (es) 1997-12-12 2000-06-09 Combinaciones de estatina-carboxialquileter

Country Status (30)

Country Link
EP (1) EP1045691B1 (https=)
JP (1) JP2002508320A (https=)
KR (1) KR20010033003A (https=)
AR (1) AR017851A1 (https=)
AT (1) ATE285762T1 (https=)
AU (1) AU754089B2 (https=)
BR (1) BR9813542A (https=)
CA (1) CA2304612A1 (https=)
CO (1) CO4970816A1 (https=)
CR (1) CR5926A (https=)
CU (1) CU20000140A7 (https=)
DE (1) DE69828442T2 (https=)
DK (1) DK1045691T3 (https=)
ES (1) ES2230733T3 (https=)
GT (1) GT199800196A (https=)
HN (1) HN1998000185A (https=)
HU (1) HUP0004547A3 (https=)
IL (1) IL135349A0 (https=)
IS (1) IS2150B (https=)
MY (1) MY118381A (https=)
NO (1) NO20002966D0 (https=)
NZ (1) NZ503982A (https=)
PA (1) PA8464601A1 (https=)
PE (1) PE20000017A1 (https=)
PL (1) PL341066A1 (https=)
PT (1) PT1045691E (https=)
SV (1) SV1998000146A (https=)
UY (1) UY25299A1 (https=)
WO (1) WO1999030704A1 (https=)
ZA (1) ZA9811348B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861555B2 (en) 2000-01-25 2005-03-01 Warner-Lambert Company Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
EP1037623A1 (en) * 1997-12-12 2000-09-27 Warner-Lambert Company Antihyperlipidemic statin-lp(a) inhibitor combinations
US20030105154A1 (en) 2001-10-24 2003-06-05 Bisgaier Charles Larry Statin-carboxyalkylether combinations
CZ20011035A3 (cs) * 1998-09-30 2001-10-17 Warner-Lambert Company Léčivo pro prevenci nebo oddálení revaskularizace pomocí katetru u pacientů postiľených chorobou koronární artérie
US6562864B1 (en) * 1999-09-02 2003-05-13 Drake Larson Catechin multimers as therapeutic drug delivery agents
IN191580B (https=) * 1999-12-17 2003-12-06 Ranbaxy Lab Ltd
CA2397960C (en) 2000-01-25 2008-09-09 Warner-Lambert Company Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
AU2001256278A1 (en) * 2000-04-18 2001-10-30 Bayer Aktiengesellschaft Use of cse inhibitors for treating heart failure
OA12252A (en) * 2000-04-26 2006-05-11 Warner Lambert Co Antihypertensive agents and use.
US6689807B1 (en) 2000-06-08 2004-02-10 Caritas St. Elizabeth's Medical Center Of Boston, Inc. HMG CoA reductase inhibitors for promoting angiogenesis
US6777552B2 (en) 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
HRPK20040255B3 (en) * 2001-08-16 2006-02-28 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
US20050026979A1 (en) * 2003-07-31 2005-02-03 Maha Ghazzi Methods for treating inflammation and inflammation-associated diseases with a statin and ether
US10028926B2 (en) * 2012-01-06 2018-07-24 Gemphire Therapeutics Inc. Methods of reducing risk of cardiovascular disease
AU2016348638A1 (en) 2015-11-06 2018-06-07 Gemphire Therapeutics Inc. Gemcabene combinations for the treatment of cardiovascular disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases

Also Published As

Publication number Publication date
HUP0004547A3 (en) 2001-12-28
EP1045691A1 (en) 2000-10-25
AU754089B2 (en) 2002-11-07
EP1045691B1 (en) 2004-12-29
PT1045691E (pt) 2005-03-31
ES2230733T3 (es) 2005-05-01
DK1045691T3 (da) 2005-03-14
AU1591599A (en) 1999-07-05
CO4970816A1 (es) 2000-11-07
BR9813542A (pt) 2000-10-10
PA8464601A1 (es) 2001-12-14
NZ503982A (en) 2002-03-28
IS2150B (is) 2006-10-13
ATE285762T1 (de) 2005-01-15
DE69828442D1 (de) 2005-02-03
GT199800196A (es) 2000-06-03
CA2304612A1 (en) 1999-06-24
NO20002966L (no) 2000-06-09
AR017851A1 (es) 2001-10-24
DE69828442T2 (de) 2005-06-02
HN1998000185A (es) 1999-06-02
CR5926A (es) 2000-03-06
IS5445A (is) 2000-04-14
MY118381A (en) 2004-10-30
UY25299A1 (es) 2001-08-27
IL135349A0 (en) 2001-05-20
PL341066A1 (en) 2001-03-26
WO1999030704A1 (en) 1999-06-24
HUP0004547A2 (hu) 2001-05-28
JP2002508320A (ja) 2002-03-19
SV1998000146A (es) 1999-09-30
PE20000017A1 (es) 2000-01-20
KR20010033003A (ko) 2001-04-25
NO20002966D0 (no) 2000-06-09
ZA9811348B (en) 1999-06-14

Similar Documents

Publication Publication Date Title
CU20000140A7 (es) Combinaciones de estatina-carboxialquileter
AR018777A1 (es) Composicion farmaceutica que contiene una combinacion de una estatina y aspirina y metodo.
ATE283050T1 (de) Zusammensetzungen mit verzögerter wirkstoffabgabe zur behandlung der hyperlipidämie
MX9702175A (es) Combinacion de un inhibidor de absorcion de colesterol y un inhibidor de sintesis de colesterol.
ES2161548T3 (es) Combinacion de un inhibidor de la aldosa reductasa y un inhibidor de la glucogeno fosforilasa.
UY25714A1 (es) Método para tratar ateroesclerosis empleando un inhibidor de ap2 y combinación.
EA200300953A1 (ru) Терапевтические комбинации для применения при сердечно-сосудистых и воспалительных заболеваниях
BG105559A (en) STABLE PHARMACEUTICAL FORMULATION COMPRISING A HMG-CoA REDUCTASE INHIBITOR
ES2182874T3 (es) Procedimiento de tratamiento de las uñas.
GT199800177A (es) Combinacion eficaz para el tratamiento de la impotencia .
EE03853B1 (et) Antitrombootiline ja antiaterogeenne farmatseutiline kompositsioon, mis sisaldab tienopüridiini derivaati ja HMG-CoA-reduktaasi inhibiitorit
EP1314425A4 (en) MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE
PT1032414E (pt) Combinacao de um inibidor da enzima de conversao da angiotensina e de um diuretico para o tratamento de perturbacoes microcirculatorias
DOP2000000022A (es) Combinacion de inhibidores de mtp e inhibidores de hmg-coa reductasa y su uso en medicametos.
FI944926L (fi) Entsymaattinen hydroksylaatiomenetelmä HMG-CoA-reduktaasi-inhibiittorien ja niiden välituotteiden valmistamiseksi
EA199901043A1 (ru) ИНГИБИТОРЫ ФАРНЕЗИЛТРАНСФЕРАЗЫ В КОМБИНАЦИИ С ИНГИБИТОРАМИ HMG-CoA-РЕДУКТАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА
AR021249A1 (es) COMPOSICIoN DE CONFITURA BLANDA NO PEGAJOSA.
PA7801701A1 (es) Compuestos ariltios
DE69008277D1 (de) 7-Subsituierte HMG-CoA-Reduktase-Inhibitoren.
ECSP982777A (es) Combinaciones de estatina- - eter carboxialquilico.
BR9813539A (pt) Combinações de inibidor de lp(a) e estatina anti-hiperlipidêmicas
PA8469001A1 (es) Combinaciones de estatina-inhibidor de mmp.
CL2004001291A1 (es) Composicion farmaceutica que comprende compuestos carbociclicos y heterociclicos; y su uso para el tratamiento o profilaxis de la infeccion por influenza.
ES2048139T1 (es) Procedimiento para la eliminacion de madera impregnada con aceite de alquitran.
DOP2001000150A (es) Agente hipertensivo y su uso